Open AccessQuantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods
Author(s) -
Camille Tron,
F. Lemaître,
Pauline Bros,
Claire Goulvestre,
Bénédicte Franck,
N. Mouton,
Sandrine Bagnos,
Romain Coriat,
Nihel Khoudour,
Dorothée Lebert,
Benoı̂t Blanchet
Publication year - 2022
Publication title -
bioanalysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.566
H-Index - 58
eISSN - 1757-6199
pISSN - 1757-6180
DOI - 10.4155/bio-2022-0057
Subject(s) - infliximab , chromatography , adalimumab , chemistry , tandem mass spectrometry , liquid chromatography–mass spectrometry , mass spectrometry , selected reaction monitoring , medicine , tumor necrosis factor alpha
Background: This study compared the performance of plasma infliximab and adalimumab quantification using a commercially available kit (mAbXmise kit) and mass spectrometry readout to that of two ELISA methods in patients treated for inflammatory bowel disease. Methods & results: The mAbXmise method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) was linear from 2 to 100 μg/ml. It was validated according to international guidelines. Regarding cross-validation for infliximab (n = 70), the mean bias with LC-MS/MS assay was approximately threefold higher with the commercial ELISA assay compared with the in-house ELISA (-6.1 vs -1.8 μg/ml, respectively). The mean bias between the LC-MS/MS assay and in-house ELISA was -1.2 μg/ml for adalimumab (n = 35). Conclusion: The LC-MS/MS method is a powerful alternative to immunoassays to monitor concentrations of infliximab and adalimumab.